VX-661

Catalog No.S7059 1 Product Citations

VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.

Price Stock Quantity  
In DMSO USD 560 In stock
USD 270 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

VX-661 Chemical Structure

VX-661 Chemical Structure
Molecular Weight: 520.5

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare CFTR Chemicals
    Compare CFTR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. Phase 2.
Targets F508del-CFTR [1]
In vitro VX-661, known as a CTFR corrector, allows F508del mutant channels to escape degradation and transit to the cell membrane.
In vivo
Features

Protocol(Only for Reference)

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Vertex to host investor conference

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-12-20)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02070744 Active, not recruiting Cystic Fibrosis Vertex Pharmaceuticals Incorporated April 2014 Phase 2
NCT02070744 Active, not recruiting Cystic Fibrosis Vertex Pharmaceuticals Incorporated April 2014 Phase 2
NCT02015507 Completed Cystic Fibrosis Vertex Pharmaceuticals Incorporated January 2014 Phase 1
NCT02015507 Completed Cystic Fibrosis Vertex Pharmaceuticals Incorporated January 2014 Phase 1
NCT01531673 Completed Cystic Fibrosis Vertex Pharmaceuticals Incorporated February 2012 Phase 2

view more

Chemical Information

Molecular Weight (MW) 520.5
Formula

C26H27F3N2O6

CAS No. 1152311-62-0
Storage 3 years -20℃Powder
6 months-80℃in solvent (DMSO, water, etc.)
Synonyms
Solubility (25°C) * In vitro DMSO 100 mg/mL (192.12 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-

Research Area

Product Citations (1)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:2

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CFTR Products

  • CFTRinh-172

    CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.

  • Selinexor (KPT-330)

    Selinexor (KPT-330) is an orally bioavailable selective CRM1 inhibitor. Phase 2.

  • BTB06584

    BTB06584 is an IF1-dependent, selective inhibitor of the mitochondrial F1 Fo-ATPase.

  • Ataluren (PTC124)

    PTC124 (Ataluren) selectively induces ribosomal read-through of premature but not normal termination codons, with EC50 of 0.1 μM, may provide treatment for genetic disorders caused by nonsense mutations (e.g. CF caused by CFTR nonsense mutation). Phase 3.

    Features:Demonstrates oral bioavailability, and an appropriate safety toxicology profile.

  • Ivacaftor (VX-770)

    Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively.

    Features:The first potent and orally available CFTR potentiator to enter human clinical trials.

  • VX-809 (Lumacaftor)

    VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM. Phase 3.

    Features:Higher specificity and efficacy relative to other CFTR defect drugs.

  • IOWH032

    IOWH032 is a synthetic CFTR inhibitor with IC50 of 1.01 μM in CHO-CFTR cell based assays. Phase 2.

  • Brefeldin A

    Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

  • Oligomycin A

    Oligomycin A is an inhibitor of ATP synthase, inhibits oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria.

  • (-)-Blebbistatin

    (-)-Blebbistatin is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

Recently Viewed Items

Tags: buy VX-661 | VX-661 supplier | purchase VX-661 | VX-661 cost | VX-661 manufacturer | order VX-661 | VX-661 distributor
Contact Us